OncoMed’s lead candidate, OMP-21M18, is currently in Phase Ib clinical trials. OncoMed’s pipeline also includes several preclinical product candidates targeting multiple validated cancer stem cell pathways.
OncoMed Pharma president and CEO Paul Hastings said that the QTDP program provides the industry with needed capital to maintain the US’ lead in biomedical innovation, support the development of medical discoveries, sustain industry growth, and improve the time and speed of the FDA and CMS in getting life-saving medicines to people.
"We are pleased to see OncoMed recognised by the award of these QTDP Program grants, which value the scope of our research and emerging pipeline of anti-cancer stem cell therapeutics programs," Hastings said.
" We look forward to applying these funds to development candidates arising from our insights into multiple cancer stem cell pathways and cancer biology."
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells.
OncoMed has formed strategic alliances with Bayer Schering Pharma and GlaxoSmithKline.